Dr. Jedd Wolchok Talks About the Phase III CheckMate 067 Trial and its Effects on Untreated Melanoma Patients
Jedd D. Wolchok, MD, PhD, chief of the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center in New York City, talks about the phase III CheckMate 067 trial.